Selskabsmeddelelser

Orphazyme announces participation in upcoming virtual investor conferences

Feb 26, 2021

Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative rare diseases, today announced that Anders Vadsholt, interim CEO and CFO of Orphazyme, will be participating in the following upcoming investor conferences.

Orphazyme announces participation in upcoming ...

Read more

Capital increase of 80,553 shares (equivalent to approximately 0.23% of the existing shares) in Orphazyme A/S as a result of an issue of bonus shares to KUMCRI and directed issuance of new shares

Feb 25, 2021

Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today decided on a capital increase as a result of a directed issue of bonus shares to the University of Kansas Medical Center Research Institute, Inc. (“KUMCRI”) and a directed issue of new shares to Kim Stratton, former CEO of the Company. The capital increase was decided pursuant to the Board of Directors’ authorization laid down in Article 3.2 and 3.3 of the Articles of Association.

Capital increase of 80 553 shares

Read more

Orphazyme to showcase data on arimoclomol in Niemann-Pick disease Type C during the 2021 Annual WORLDSymposium™

Feb 4, 2021

Orphazyme US (ORPH), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced plans to present a series of data on its investigational drug arimoclomol during the 17th Annual WORLDSymposium Scientific Meeting, to be held virtually on February 8-12, 2021.

Orphazyme to showcase data on arimoclomol in niemann

Read more

Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities

Feb 1, 2021

Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme.

Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities

Read more

Capital increase of 170,131 shares in Orphazyme A/S as a result of vesting and exercise of Matching Shares

Feb 1, 2021

Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of  neurodegenerative orphan diseases, today announces that a share capital increase has been registered with the Danish Business Authority as a result of the vesting and exercise of Matching Shares. A total of 170,131 shares of nominally DKK 1 each have been issued by the Company at a subscription price per Matching Share of DKK 1.

Capital increase of 170 131 shares in orphazyme

Read more

Major shareholder announcement

Jan 18, 2021

Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from Danske Bank A/S, that as of January 15, 2021, Danske Bank A/S holds a total of 34,697,703 shares in the Company, corresponding to 3.49% of the Company’s share capital and that Danske Bank A/S as of January 15, 2021 controls 4.95% of the voting rights in the Company.

Major shareholder announcement

Read more

Orphazyme to take part in panel discussion at the LifeSci Partners 10th Annual Healthcare Corporate Access Event

Jan 4, 2021

Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces Anders Vadsholt, Chief Financial Officer of Orphazyme, will take part in a panel discussion at the LifeSci Partners 10th Annual Healthcare Corporate Access Event, which is being held virtually from January 6-8 and 11-14, 2021.

Orphazyme to take part in panel discussion

Read more

1 2 3 4